For instance, Ciardiello et al. indicated that the NLR could be a valuable biomarker for identifying candidates likely to benefit from cetuximab plus avelumab therapy in RAS/BRAF wild-type ctDNA CRC patients [39]. Here, BRAF is linked to colorectal carcinoma.